Biotech news
Refine search
Regulation & Industry
Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices. 27 August 2026
Biotech
As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler 27 August 2026
Regulation & Industry
While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal. 25 August 2026
Careers
The four-person team adds significant life sciences experience to the litigation boutique, drawn to move firms by Stris’ “outstanding trial lawyers” and “sophisticated appellate capabilities”. 24 August 2026
Biotech
Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings. 20 August 2026
Biotech
Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains. 17 August 2026
Careers
With more than 25 years’ experience, the ex-EIP partner specialises in technology and life sciences, particularly SEPs and FRAND in the UK and Europe. 5 August 2026
Regulation & Industry
Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come? 29 July 2026
Regulation & Industry
With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last? 27 July 2026
Careers
The firm has added partners with expertise in life sciences, technology disputes and trademark strategy, alongside leadership changes at its Hong Kong affiliate. 27 July 2026


